Target Name: ZFP36
NCBI ID: G7538
Review Report on ZFP36 Target / Biomarker Content of Review Report on ZFP36 Target / Biomarker
ZFP36
Other Name(s): tristetraproline | Zfp-36 | NUP475 | Zinc finger protein, C3H type, 36 homolog | growth factor-inducible nuclear protein NUP475 | RNF162A | zinc finger protein 36, C3H type, homolog | zfp-36 | ZFP36 ring finger protein | MRNA decay activator protein ZFP36 | TTP_HUMAN | Tristetraprolin | G0/G1 switch regulatory protein 24 | GOS24 | G0S24 | Growth factor-inducible nuclear protein NUP475 | tristetraprolin | TIS11 | Zinc finger protein 36 | mRNA decay activator protein ZFP36 | zinc finger protein 36 homolog | TTP

ZFP36: A Promising Drug Candidate for Neurological Disorders

Tristetraproline, or ZFP36, is a drug candidate for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It is a small molecule that can modulate the activity of dopamine receptors, which are involved in the treatment of many neurological disorders.

ZFP36 works by binding to dopamine receptors and increasing the amount of dopamine available in the brain. This increase in dopamine can help to alleviate symptoms of these disorders, such as tremors, stiffness, and difficulty with movement.

One of the key benefits of ZFP36 is its ability to cross the blood-brain barrier and its low toxicity. The blood-brain barrier is a specialized barrier that separates the brain from the bloodstream, and it is difficult for drugs to penetrate it. However, ZFP36 has been shown to be able to cross the blood-brain barrier and to have a low toxicity profile.

In addition to its potential use in treating neurological disorders, ZFP36 also has the potential to be a biomarker for certain neurological disorders. The ability of ZFP36 to modulate dopamine receptors makes it a promising candidate for the treatment of disorders that are characterized by the overuse or underuse of dopamine. For example, ZFP36 may be a good treatment for addiction, as it can help to reduce the cravings for drugs.

ZFP36 is also a good candidate for the treatment of certain neurological disorders that are characterized by inflammation. For example, it may be a good treatment for Alzheimer's disease, as it has been shown to have anti-inflammatory properties.

In conclusion, ZFP36 is a promising drug candidate for the treatment of various neurological disorders. Its ability to modulate dopamine receptors and its low toxicity make it a promising candidate for the treatment of many disorders. Additionally, its potential as a biomarker for certain neurological disorders makes it a promising candidate for the development of new diagnostic tools. Further research is needed to fully understand the potential of ZFP36 and to determine its safety and efficacy as a treatment for neurological disorders.

Protein Name: ZFP36 Ring Finger Protein

Functions: Zinc-finger RNA-binding protein that destabilizes several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis (PubMed:9703499, PubMed:10330172, PubMed:10751406, PubMed:11279239, PubMed:12115244, PubMed:12748283, PubMed:15187101, PubMed:15634918, PubMed:17030620, PubMed:16702957, PubMed:20702587, PubMed:20221403, PubMed:21775632, PubMed:27193233, PubMed:23644599, PubMed:25815583, PubMed:31439631). Acts as an 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signaling events to the mRNA decay machinery (PubMed:15687258, PubMed:23644599). Recruits deadenylase CNOT7 (and probably the CCR4-NOT complex) via association with CNOT1, and hence promotes ARE-mediated mRNA deadenylation (PubMed:23644599). Functions also by recruiting components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs (PubMed:11719186, PubMed:12748283, PubMed:15687258, PubMed:16364915). Self regulates by destabilizing its own mRNA (PubMed:15187101). Binds to 3'-UTR ARE of numerous mRNAs and of its own mRNA (PubMed:10330172, PubMed:10751406, PubMed:12115244, PubMed:15187101, PubMed:15634918, PubMed:17030620, PubMed:16702957, PubMed:19188452, PubMed:20702587, PubMed:20221403, PubMed:21775632, PubMed:25815583). Plays a role in anti-inflammatory responses; suppresses tumor necrosis factor (TNF)-alpha production by stimulating ARE-mediated TNF-alpha mRNA decay and several other inflammatory ARE-containing mRNAs in interferon (IFN)- and/or lipopolysaccharide (LPS)-induced macrophages (By similarity). Also plays a role in the regulation of dendritic cell maturation at the post-transcriptional level, and hence operates as part of a negative feedback loop to limit the inflammatory response (PubMed:18367721). Promotes ARE-mediated mRNA decay of hypoxia-inducible factor HIF1A mRNA during the response of endothelial cells to hypoxia (PubMed:21775632). Positively regulates early adipogenesis of preadipocytes by promoting ARE-mediated mRNA decay of immediate early genes (IEGs) (By similarity). Negatively regulates hematopoietic/erythroid cell differentiation by promoting ARE-mediated mRNA decay of the transcription factor STAT5B mRNA (PubMed:20702587). Plays a role in maintaining skeletal muscle satellite cell quiescence by promoting ARE-mediated mRNA decay of the myogenic determination factor MYOD1 mRNA (By similarity). Associates also with and regulates the expression of non-ARE-containing target mRNAs at the post-transcriptional level, such as MHC class I mRNAs (PubMed:18367721). Participates in association with argonaute RISC catalytic components in the ARE-mediated mRNA decay mechanism; assists microRNA (miRNA) targeting ARE-containing mRNAs (PubMed:15766526). May also play a role in the regulation of cytoplasmic mRNA decapping; enhances decapping of ARE-containing RNAs, in vitro (PubMed:16364915). Involved in the delivery of target ARE-mRNAs to processing bodies (PBs) (PubMed:17369404). In addition to its cytosolic mRNA-decay function, affects nuclear pre-mRNA processing (By similarity). Negatively regulates nuclear poly(A)-binding protein PABPN1-stimulated polyadenylation activity on ARE-containing pre-mRNA during LPS-stimulated macrophages (By similarity). Also involved in the regulation of stress granule (SG) and P-body (PB) formation and fusion (By similarity). Plays a role in the regulation of keratinocyte proliferation, differentiation and apoptosis (PubMed:27182009). Plays a role as a tumor suppressor by inhibiting cell proliferation in breast cancer cells (PubMed:26926077)

The "ZFP36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZFP36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZFP36L1 | ZFP36L2 | ZFP37 | ZFP41 | ZFP42 | ZFP57 | ZFP62 | ZFP64 | ZFP64P1 | ZFP69 | ZFP69B | ZFP82 | ZFP90 | ZFP91 | ZFP91-CNTF | ZFP92 | ZFPL1 | ZFPM1 | ZFPM2 | ZFPM2-AS1 | ZFR | ZFR2 | ZFTA | ZFTRAF1 | ZFX | ZFX-AS1 | ZFY | ZFYVE1 | ZFYVE16 | ZFYVE19 | ZFYVE21 | ZFYVE26 | ZFYVE27 | ZFYVE28 | ZFYVE9 | ZFYVE9P1 | ZG16 | ZG16B | ZGLP1 | ZGPAT | ZGRF1 | ZHX1 | ZHX1-C8orf76 | ZHX2 | ZHX3 | ZIC1 | ZIC2 | ZIC3 | ZIC4 | ZIC5 | ZIK1 | ZIM2 | ZIM3 | Zinc finger protein GLI | ZKSCAN1 | ZKSCAN2 | ZKSCAN3 | ZKSCAN4 | ZKSCAN5 | ZKSCAN7 | ZKSCAN8 | ZKSCAN8P1 | ZMAT1 | ZMAT2 | ZMAT3 | ZMAT4 | ZMAT5 | ZMIZ1 | ZMIZ1-AS1 | ZMIZ2 | ZMPSTE24 | ZMYM1 | ZMYM2 | ZMYM3 | ZMYM4 | ZMYM4-AS1 | ZMYM5 | ZMYM6 | ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135